Mankind Pharma schedules board meeting on 30 July to approve Q1 FY2026 unaudited results

What Mankind Pharma announced

Mankind Pharma Ltd filed a notice with BSE on 16 July 2026 stating that its Board of Directors will meet on 30 July 2026. The agenda includes the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.

The filing does not provide any quantitative details of revenue, profit, or margins for the quarter. It merely informs shareholders and the market of the upcoming board meeting and the purpose of that meeting.

Board meeting details

• Date of meeting: 30 July 2026
• Purpose: Approval of unaudited financial results (standalone and consolidated) for Q1 FY2026.
• Filing date: 16 July 2026 (timestamp 11:02:17 UTC).
• Regulatory channel: BSE corporate filing (PDF link provided in the source).

The board’s approval is a standard procedural step before the company can file audited results with the stock exchanges and the Ministry of Corporate Affairs.

Financial results – unaudited status

The notice confirms that the results for the quarter ending 30 June 2026 are unaudited. This means the figures have not yet been examined by independent auditors and are subject to change after the audit. The filing does not disclose any specific numbers such as turnover, net profit, or earnings per share.

"The meeting of the Board of Directors of the Company is scheduled on 30/07/2026, inter alia, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2026."

Key facts at a glance

Why this matters for investors

The board’s approval of unaudited results is a routine compliance requirement. It signals that the company is on track to complete its quarterly reporting cycle. While no performance figures are disclosed, investors can expect that audited results will be filed later, after the audit is completed. The timing of the board meeting also indicates the company’s internal reporting schedule.

Conclusion

Mankind Pharma has formally announced a board meeting on 30 July 2026 to approve its unaudited Q1 FY2026 financial results. The filing contains no quantitative data, and the results remain subject to audit. Investors will need to await the audited financial statements for detailed performance insight.